Autologous Adipose-Derived Stem Cells(Regeneration Biomedical, Inc.…

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 15 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 1

Clinical phase

Not yet recruiting

Recruitment status

not reported

Planned enrollment

2028-09-01

Primary-completion proxy

Executive view

NCT07373067 evaluates Autologous Adipose-Derived Stem Cells(Regeneration Biomedical, Inc.) in Alzheimer Disease. The disclosed sponsor is Regeneration Biomedical, Inc., the design is Interventional, and the geographic footprint is Geography not reported. The first listed primary endpoint is The safety of repeated RB-ADSC treatment in study participants with AD, assessed over up to 12 months.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07373067 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Alzheimer Disease landscape. Drug & Asset MCP drug_fetch was queried for Autologous Adipose-Derived Stem Cells(Regeneration Biomedical, Inc.), while Company & Deal Intelligence MCP organization_fetch was queried for Regeneration Biomedical, Inc..

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07373067	Autologous Adipose-Derived Stem Cells(Regeneration Biomedical, Inc.)	Phase 1 / Not yet recruiting	Regeneration Biomedical, Inc.	Geography not reported	The safety of repeated RB-ADSC treatment in study participants with AD up to 12 months	2028-09-01
NCT07512362	Allogeneic human mesenchymal stem cells(University of Miami)	Phase 2 / Recruiting	University of Miami	United States	Change in Alzheimer's Disease Scale-Cognitive Subscale (ADAS-Cog) Baseline, Week 16, Week 32, and Week 48	2028-06-15
NCT07496021	CKDB-001	Not Applicable / Recruiting	CKD Bio Corp.	South Korea	Change from baseline in the ADAS-Cog 14 total score at Weeks 12 and 24 Baseline, Week 12, Week 24	2027-05-31
NCT07489599	QLH2405	Phase 1 / Not yet recruiting	Qilu Pharmaceutical Co., Ltd.	Geography not reported	Adverse Events (AEs) Up to approximately 28 weeks	2027-03-01
TCTR20260320005	Laromestracel	Phase 1/2 / Pending (Not yet recruiting)	Sponsor not reported	China		2026-07-30

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07373067 is a Phase 1, not yet recruiting study with not reported planned participants. Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Single Group Assignment.

The primary endpoint is “The safety of repeated RB-ADSC treatment in study participants with AD” over “up to 12 months.” The retrieved endpoint description is: Safety will be determined by incidence, type and severity of adverse events (AE) and serious adverse events (SAE) graded according to CTCAE v5.0 and CRS revised grading system and defined by clinical relevant findings at every visit and 2 month following last dose in physical examination, vital signs and laboratory data.

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

0 recent result records were selected as contextual evidence for Alzheimer Disease. These records do not establish direct evidence for NCT07373067 unless the registration number matches.

Indexed evidence status

No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Autologous Adipose-Derived Stem Cells(Regeneration Biomedical, Inc.) is indexed as Stem cell therapy with target not reported biology and a global stage of Phase 2. The asset profile lists Regeneration Biomedical, Inc. as an originator or developer.

Regeneration Biomedical, Inc. is indexed in an unreported country with the website https://www.regenerationbiomedical.com. Regeneration Biomedical develops autologous stem cell therapies for neurodegenerative diseases using patients' own cells. The record lists 1 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Autologous Adipose-Derived Stem Cells(Regeneration Biomedical, Inc.) is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07373067
Protocol source: https://clinicaltrials.gov/study/NCT07373067
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 15 October 2026.

Autologous Adipose-Derived Stem Cells(Regeneration Biomedical, Inc.) in Alzheimer Disease is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes The safety of repeated RB-ADSC treatment in study participants with AD and 2028-09-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP